1. 诺华
  2. 索雷尔
  3. Xolair
  4. 奥马珠单抗
  5. omalizumab
  6. 慢性自发性荨麻疹
  7. CSU

来源:生物谷 2014-03-06 15:54


2014年3月6日讯 /生物谷BIOON/ --诺华(Novartis)3月6日宣布,单抗药Xolair(omalizumab,奥马珠单抗)获欧盟委员会(EC)批准,作为一种附加药物,用于对H1抗组胺药物反应不足的12岁及以上青少年和成人慢性自发性荨麻疹(CSU)患者的治疗,获批的剂量300mg,每4周皮下注射一次。

Xolair的获批,是基于3项关键性III期注册研究(ASTERIA I、ASTERIA II、GLACIAL)的积极及一致性结果。这些研究涉及近1000名对抗组胺药物不响应的CSU患者,研究结果表明,300mg剂量omalizumab达到了所有的主要终点及预先指定的次要终点,表明omalizumab能够显著改善瘙痒和荨麻疹,包括快速缓解瘙痒,并在许多情况下完全清除症状。在整个III期项目中,300mg剂量omalizumab治疗组,生活质量显著改善。






英文原文:Novartis: European Commission Approves Xolair

Basel, 6 March 2014 - Novartis announced today that the European Commission (EC) has approved the use of Xolair® (omalizumab) as an add-on therapy for the treatment of chronic spontaneous urticaria (CSU) in adult and adolescent (12 years and above) patients with inadequate response to H1-antihistamine treatment. The approved dose is 300 mg by subcutaneous injection every four weeks.

"The EU approval of Xolairin CSU is truly exciting for patients with this chronic and debilitating skin disease," said David Epstein, Division Head of Novartis Pharmaceuticals. "With this new therapeutic option from our specialty dermatology portfolio, our aim is to help ensure that the up to 50% of patients who suffer from CSU and don't respond to approved doses of antihistamines have access to Xolairas quickly as possible in the EU."

At any given time, the prevalence of chronic urticaria (CU) is up to 1% of the world's population[5], and up to two thirds of these patients have CSU[5],[6]. CSU is also known as chronic idiopathic urticaria (CIU) in the US, and is a severe and distressing skin condition characterized by red, swollen, itchy and sometimes painful hives or wheals on the skin that spontaneously present and reoccur for more than six weeks[2]-[4]. Up to 40% of CSU patients also experience angioedema, a swelling in the deep layers of the skin[1].

The EU approval follows the Committee for Medicinal Products for Human Use (CHMP) positive opinion on Xolair, which was adopted based on positive and consistent results from three pivotal Phase III registration studies (ASTERIA I, ASTERIA II and GLACIAL) that involved nearly 1,000 patients with CSU not responding to H1-antihistamines[7]-[9]. Xolair 300 mg met all primary and pre-specified secondary endpoints across these studies, which showed Xolair significantly improved itch and hives, including rapid itch relief, and in many cases completely cleared symptoms[7]-[9]. Quality of life was also significantly improved for patients treated with Xolair 300 mg[1]-[3]across the Phase III study program. Negative effects of CSU on quality of life may include sleep deprivation and psychological comorbidities such as depression and anxiety[5],[10].

Results from the three pivotal registration studies for Xolair in CSU were announced in 2013. Highlights from these studies that were previously reported include:

In all three Phase III studies, a significant proportion of patients became either completely free of itch and hives (range 34-44%; p<0.001 to p<0.0001 at 300 mg) or had their symptoms suppressed to minimal levels (52-66%;p<0.0001 at 300mg)[7]-[9].
In the ASTERIA II study, 44% of patients receiving Xolair 300 mg were itch-and hive-free after 12 weeks of treatment (p<0.0001)[9].
In the ASTERIA I study, Xolair-treated patients experienced a rapid reduction in itch and hives as early as Week 1, with the therapeutic benefit sustained over 24 weeks of active treatment (p<0.0001)[7].
In the GLACIAL study, more than half of patients had failed multiple therapies including H1-antihistamines (at up to four times the approved dose) and H2-antihistamines and/or leukotriene receptor antagonists (LTRAs)[8]. Patient response in GLACIAL was similar to that seen in ASTERIA I and II, leading to elimination or suppression of symptoms to minimal levels within 2 weeks of the start of treatment, and sustained throughout the 24 week treatment period[7]-[9].
In the pivotal Phase III studies, the incidence and severity of adverse events (AEs) was similar between Xolair and placebo recipients[7]-[9].

In addition to the EU, Xolair has been approved for the treatment of CSU in five countries: Egypt, Turkey, Guatemala, El Salvador and Bangladesh. Regulatory reviews are currently ongoing in more than 20 countries, including the US, Canada, Australia and Switzerland.

Xolair is being jointly developed by Novartis and Genentech, Inc.

About the Pivotal Phase III Xolair CSU Studies
Three pivotal Phase III studies, ASTERIA I, ASTERIA II and GLACIAL, evaluated the efficacy and safety of Xolair in nearly 1,000 CSU patients not responding to antihistamines[7]-[9].

ASTERIA I and ASTERIA II were global, multi-center, randomized double-blind studies that evaluated the efficacy and safety of Xolair compared to placebo. The studies enrolled 323 patients and 318 patients respectively, aged between 12 and 75 with moderate to severe CSU[7],[9]. Patients were randomized to Xolair 75 mg, 150 mg or 300 mg or placebo, given subcutaneously every four weeks[7],[9]. ASTERIA I had a 24-week treatment period, with a 16-week follow-up and ASTERIA II had a 12-week treatment period, with a 16-week follow-up period[7],[9].

GLACIAL was a 40-week, global, multi-center, randomized double-blind study that evaluated the safety and efficacy of Xolair compared to placebo[8]. It involved 335 patients aged between 12 and 75 with moderate to severe CSU despite receiving standard-of-care therapy, consisting of concomitant H1-antihistamine therapy (up to four times the approved dose) and other background medications including H2-antihistamines and/or leukotriene receptor antagonists (LTRAs)[8]. Patients were randomized to Xolair 300 mg or placebo (3:1), given subcutaneously every four weeks for a total period of 24 weeks[8].

About Xolair® (omalizumab)
Xolair is a targeted therapy that binds to immunoglobulin E (IgE). Xolair suppresses histamine-induced skin reactions, probably through its reduction of IgE and downstream effects on cellular activation mechanisms[11]. Research is ongoing to understand the mechanism of action of Xolair in CSU, which could lead to a deeper understanding of how the disease develops[1].

In addition to the EU, Xolair is currently approved for the treatment of CSU in five other countries. It is approved for the treatment of moderate to severe persistent allergic asthma in more than 90 countries, including the US since 2003 and the EU since 2005 and has over 400,000 patient years of exposure. In the EU, it is also approved for the treatment of severe persistent allergic asthma in children (aged six and above), adolescents and adults. In addition, a liquid formulation of Xolair in pre-filled syringes has been approved in the EU and launched in most European countries. In the US, Xolair for subcutaneous use in appropriate allergic asthma patients is co-promoted by Novartis Pharmaceuticals Corporation and Genentech, Inc.

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->